Drug Profile
REP 2139
Alternative Names: REP 2139; REP 2139 calcium chelate; REP 2139 magnesium chelate; REP 2139-Ca; REP 2139-Mg; REP 9AC'Latest Information Update: 02 Jan 2024
Price :
$50
*
At a glance
- Originator REPLICor
- Class Antivirals; Nucleic acids; Oligonucleotides; Polymers
- Mechanism of Action Hepatitis B virus replication inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Hepatitis B; Hepatitis D
Most Recent Events
- 10 Nov 2023 Efficacy and adverse events data from compassionate access trial in Hepatitis B and Hepatitis D presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 10 Nov 2023 Efficacy and adverse events data from a clinical trial in Hepatitis B and Hepatitis D presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 10 Nov 2023 Therapeutics data from a phase II trial in Hepatitis B presented 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)